Versant Capital Management Inc Buys 1,208 Shares of Boston Scientific Co. (NYSE:BSX)

Versant Capital Management Inc grew its position in shares of Boston Scientific Co. (NYSE:BSX) by 109.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,314 shares of the medical equipment provider’s stock after purchasing an additional 1,208 shares during the period. Versant Capital Management Inc’s holdings in Boston Scientific were worth $207,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in BSX. TD Asset Management Inc raised its holdings in shares of Boston Scientific by 4.6% during the 2nd quarter. TD Asset Management Inc now owns 2,152,974 shares of the medical equipment provider’s stock worth $165,801,000 after acquiring an additional 93,713 shares in the last quarter. National Bank of Canada FI grew its stake in shares of Boston Scientific by 109.0% in the 2nd quarter. National Bank of Canada FI now owns 441,670 shares of the medical equipment provider’s stock worth $33,746,000 after buying an additional 230,323 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Boston Scientific by 1.4% in the 2nd quarter. Arizona State Retirement System now owns 426,131 shares of the medical equipment provider’s stock worth $32,816,000 after buying an additional 5,730 shares during the last quarter. Impax Asset Management Group plc raised its position in shares of Boston Scientific by 4.2% during the 2nd quarter. Impax Asset Management Group plc now owns 4,654,771 shares of the medical equipment provider’s stock valued at $357,570,000 after buying an additional 189,705 shares in the last quarter. Finally, New York Life Investment Management LLC raised its position in shares of Boston Scientific by 0.5% during the 2nd quarter. New York Life Investment Management LLC now owns 206,888 shares of the medical equipment provider’s stock valued at $15,932,000 after buying an additional 1,017 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $85.00, for a total value of $11,264,795.00. Following the sale, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. This represents a 45.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the transaction, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 325,293 shares of company stock worth $27,742,874. 0.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have weighed in on BSX. Truist Financial boosted their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. BTIG Research boosted their target price on Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Royal Bank of Canada raised their price target on Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Sanford C. Bernstein boosted their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Finally, Needham & Company LLC restated a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 27th. Four research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

Boston Scientific Trading Up 1.5 %

NYSE:BSX opened at $90.69 on Friday. The stock has a market capitalization of $133.66 billion, a price-to-earnings ratio of 74.95, a PEG ratio of 2.67 and a beta of 0.80. Boston Scientific Co. has a 52 week low of $57.58 and a 52 week high of $91.93. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm has a 50 day moving average of $88.86 and a 200 day moving average of $83.10.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter last year, the company earned $0.50 earnings per share. The company’s quarterly revenue was up 19.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.